PERSIA-HOCM: how to read a prospective observational study protocol
بروتوكول PERSIA-HOCM: كيف نقرأ بروتوكول دراسة رصدية مستقبلية؟
Journal: BMJ open
University: 19 cardiovascular referral centres in Iran
Study Type: protocol
Evidence Level: preliminary
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
This BMJ Open paper is a protocol for a prospective, multicentre observational study in Iran. It describes planned methods and outcomes; it does not report participant results or establish the safety or effectiveness of mavacamten.
1-Minute Summary
PERSIA-HOCM is a published protocol for a planned prospective observational cohort across 19 cardiovascular referral centres in Iran. The researchers intend to follow eligible adults receiving mavacamten in routine care and document predefined clinical, imaging, safety, adherence and quality-of-life measures. Because this is a protocol, there are no study results to interpret yet. Its main value is transparency about the planned design. Any future findings will need to be evaluated separately, with attention to the non-randomised design, possible confounding, selection bias, sponsor involvement and the limits of observational evidence.
3-Minute Summary
The publication describes the design of PERSIA-HOCM, not the outcome of a completed study. It plans a prospective, multicentre, observational cohort in Iran. Adults who meet the protocol's eligibility criteria and receive mavacamten through routine clinical care are intended to be followed over time. The protocol identifies clinical, imaging, safety, adherence, biomarker and quality-of-life measures that the investigators plan to collect. A protocol improves research transparency because it documents intended methods and outcomes before final results are available. It does not demonstrate that the studied medicine is safe or effective, and it should not be read as a treatment recommendation. The paper's background discussion cites earlier literature, but those statements are not findings from PERSIA-HOCM. The planned design can contribute information about routine practice in a setting that may be under-represented in previous research. At the same time, an observational, non-randomised design cannot establish causation as strongly as a randomised trial. Confounding, selection, measurement variability and sponsor involvement are important considerations for later appraisal. The appropriate conclusion today is limited: the investigators have published a plan for collecting and analysing future data. Readers should wait for peer-reviewed results, compare them with the registered methods and assess the completed study independently. Medication decisions belong with qualified clinicians who know the person's diagnosis, monitoring requirements and local prescribing rules.
Full Analysis
## What was published? PERSIA-HOCM is a study protocol published in BMJ Open. A protocol records what researchers plan to do; it is not a report of completed participant outcomes. ## Planned design The paper describes a prospective, multicentre, observational study across cardiovascular referral centres in Iran. It defines eligibility criteria, planned follow-up, data collection and outcomes the team intends to assess. Treatment is not assigned by the study; participants receive care through routine clinical practice. ## What can be concluded now? The protocol shows that a structured study has been planned. It provides no PERSIA-HOCM results and cannot establish the medicine's safety, effectiveness or suitability for any individual. Statements in the background about earlier trials are context supplied by the authors, not new findings from this protocol. ## How should future results be appraised? Readers should compare the eventual report with the published protocol, check whether planned outcomes and follow-up were completed, and examine missing data, selection, confounding, measurement consistency, adverse-event reporting, funding and conflicts of interest. Because the study is observational and non-randomised, future associations will require cautious interpretation. ## Source BMJ Open protocol, DOI: 10.1136/bmjopen-2026-124273. Read the original publication. Explore ATHAR's research-literacy resources.Health Implications
This protocol does not provide personal medical guidance or study results. Use it to understand planned research methods, and discuss diagnosis, monitoring or medication questions with a qualified clinician.
Key Findings
- This is a protocol, not a completed-results paper.
- The planned study is prospective, multicentre, observational and non-randomised.
- No conclusion about safety or effectiveness can be drawn from the protocol itself.